Shares of Vanda Pharmaceuticals (NASDAQ: VNDA) traded up more than 29 percent following the company's 8-K filing on Wednesday and Exhibit 99.1 presentation.
History of the Drug Application
On May 31, 2013, Vanda announced that it submitted...
NEW YORK (TheStreet) -- Vanda Pharmaceuticals surged Wednesday after the European Medicines Agency accepted the company's Marketing Authorization Application for Hetlioz, or tasimelteon, a medication that treats non-24-hour sleep-wake...
Capital Essence's Investment Blog- 錢途集團 » Page not foundMar 14Comment
Thursday bearish breakdown suggested that short-term overbought correction off the March high of 1883 on the S&P 500 index had evolved into an intermediate-term downtrend with downside target of 1828, which we’ve determined using the trend...
Vanda Pharmaceuticals (VNDA)
Q4 2013 Earnings Call
February 13, 2014 10:00 am ET
James Patrick Kelly - Chief Financial Officer, Principal Accounting Officer, Senior Vice President, Treasurer and Secretary
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Vanda Pharmaceuticals (VNDA):